TICKERNERD
Menu
ACHVACHVHealthcare · Biotechnology

ACHV Stock Forecast: Achieve Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$6.83
−5.01% on the day

The 12 Wall Street analysts covering Achieve Life Sciences, Inc. hold a median 12-month price target of $13 — +90.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$704.2M
Ticker Nerd rank
36/ 100
Median analyst target
$13
Analysts covering
12
Revenue$0.0
Operating income−$18.4M
Net income−$74.8M
Free cash flow−$11.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.2%
1M
−15.6%
YTD
+37.4%
1Y
+30.3%
From 52W high
−19.9%
From 52W low
+157.7%
$2.65
$8.53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACHV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Achieve Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
36/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Accruals
82
Size
48
Value
47
Growth
44
Revisions
39
Volatility
25
Quality
15
Issuance
12

Momentum (95): The shares have been drifting up relative to others.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACHV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACHV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26ACHVHigh $21Median $13Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $9Median $13High $21

The green dot is the last close — the median target sits +90.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Sept 2026StifelInitiatesBuy$18
13 Aug 2026Morgan StanleyInitiatesOverweight—
13 Aug 2026Morgan StanleyInitiatesOverweight$13
22 June 2026HC Wainwright & Co.ReiteratesBuy$12
22 June 2026HC Wainwright & Co.ReiteratesBuy—
21 Apr 2026Canaccord GenuityInitiatesBuy—
16 Apr 2026HC Wainwright & Co.ReiteratesBuy—
25 Mar 2026HC Wainwright & Co.ReiteratesBuy—
25 Nov 2025CitizensInitiatesMarket Outperform—
21 Aug 2025HC Wainwright & Co.InitiatesBuy—
14 Nov 2024Rodman & RenshawInitiatesBuy—
27 Sept 2024Raymond JamesInitiatesStrong Buy$20
15 Aug 2024OppenheimerReiteratesOutperform—
13 May 2024OppenheimerMaintainsOutperform—
17 Apr 2024JonesTradingInitiatesBuy—
1 Apr 2024OppenheimerReiteratesOutperform—
5 Mar 2024Lake StreetMaintainsBuy—
12 Dec 2023OppenheimerMaintainsOutperform—
1 June 2023Lake StreetMaintainsBuy—
31 May 2023Lake StreetMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ACHV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACHV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Achieve Life Sciences, Inc. returned +30.3% against +12.4% for the S&P 500, dividends included.

ACHV vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26ACHVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACHV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Achieve Life Sciences, Inc. (ACHV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
−43.5×

Cheaper than 99% of US stocks

EV / EBITDA
−9.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−845.0%

Higher than 2% of US stocks

Return on assets
−29.2%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Achieve Life Sciences, Inc. (ACHV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Achieve Life Sciences, Inc. has a market value of $704.2M and an enterprise value of $530.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$114.0M.

  • Diluted earnings per share, trailing twelve months: $−1.55.

  • Free cash flow in the twelve months to 30 June 2026: −$47.2M.

  • Shares outstanding: 102.7M.

  • Trailing P/E: −5.5×; forward P/E: −10.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Achieve Life Sciences, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

ACHV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACHVAchieve Life Sciences, Inc.$704.2M36
SGMTSagimet Biosciences, Inc.$697.8M44
ATTOAttovia Therapeutics, Inc.$692.3M0
WVEWave Life Sciences, Inc.$690.6M21
APMDApnimed, Inc.$682.6M1
DNAGinkgo Bioworks Holdings, Inc.$726.0M43
SLBTSL Science Holding Ltd.$672.9M0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Achieve Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACHV news & analysis

Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026

GlobeNewsWire · 21 Oct 2026positive

Achieve Life Sciences reported positive 52-week efficacy results from its open-label ORCA-OL trial of cytisinicline for smoking and e-cigarette cessation at the CHEST 2026 Annual Meeting. Nearly one in three participants who continued smoking or vaping after a prior ORCA trial had quit by the end of treatment; the quit rate was 39% among participants previously assigned placebo.

Why it matters — The results provide longer-term trial data on cytisinicline’s potential for smoking and vaping cessation, relevant to ACHV’s development program.

Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications

GlobeNewsWire · 7 Oct 2026positive

Achieve Life Sciences appointed Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. She joins the executive team and will lead marketing, brand strategy, and corporate communications as the company prepares for the potential commercialization of cytisinicline.

Why it matters — The appointment adds a senior marketing and communications leader as Achieve prepares for potential commercialization of its nicotine-dependence treatment.

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

GlobeNewsWire · 6 Oct 2026neutral

Achieve Life Sciences announced that its board approved stock options covering 46,500 shares and RSUs covering 44,500 shares for four new employees. It also approved an inducement award for newly appointed CFO Benjamin Halladay, comprising an option for up to 200,000 shares and 200,000 RSUs.

Why it matters — The awards disclose the share-based compensation granted to new employees and the company's new CFO.

Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer

GlobeNewsWire · 1 Oct 2026positive

Achieve Life Sciences announced the appointment of Benjamin Halladay as Chief Financial Officer, citing his public company CFO experience across commercial pharma and business development as the company prepares for the potential commercialization of cytisinicline.

Why it matters — A new CFO with commercial pharma and public company experience strengthens Achieve's executive leadership as it advances toward potential commercialization of its lead candidate, cytisinicline.

Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026

GlobeNewsWire · 28 Sept 2026neutral

Achieve Life Sciences announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at the CHEST 2026 conference in Phoenix, Arizona, October 18-21.

Why it matters — The presentation of long-term cytisinicline efficacy data is relevant for ACHV watchers as it concerns the company's lead product candidate for nicotine dependence.

FAQ

Frequently asked questions about ACHV stock

What is the ACHV stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Achieve Life Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACHV stock a buy right now?

Of the 12 analysts covering Achieve Life Sciences, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Achieve Life Sciences, Inc. 36 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACHV?

As at 31 Oct 2026, Achieve Life Sciences, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will ACHV stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +90.3% from the last close, and Ticker Nerd's factor model ranks Achieve Life Sciences, Inc. 36 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACHV stock forecast for 2030?

No analyst covering Achieve Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACHV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.

How has ACHV stock performed over the past year?

Achieve Life Sciences, Inc. returned +30.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Achieve Life Sciences, Inc. do?

Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing cytisinicline, a treatment designed to address nicotine dependence and support smoking cessation.

What is the latest news on ACHV?

The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026". Achieve Life Sciences reported positive 52-week efficacy results from its open-label ORCA-OL trial of cytisinicline for smoking and e-cigarette cessation at the CHEST 2026 Annual Meeting. Nearly one in three participants who continued smoking or vaping after a prior ORCA trial had quit by the end of treatment; the quit rate was 39% among participants previously assigned placebo.

Company

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing cytisinicline, a treatment designed to address nicotine dependence and support smoking cessation. Its core work centers on advancing this non-opioid, plant-derived therapy for adults seeking help with nicotine withdrawal and tobacco use disorder. The company operates in the healthcare and biotechnology sectors, where it contributes to efforts aimed at expanding pharmacological options for addiction treatment. Achieve Life Sciences’ current business is centered on cytisinicline across key markets in North America and the United Kingdom, reflecting its focus on regulated prescription therapies for nicotine addiction. Headquartered in Bothell, Washington, with operations also connected to Vancouver, British Columbia, the company remains dedicated to a single therapeutic area and a narrowly defined pharmaceutical portfolio.

CEO Dr. Andrew D. Goldberg M.D. · 28 employees · United States · https://www.achievelifesciences.com